Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
29 April 2022 - 9:05PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on sickle cell
disease, prostate cancer and other rare hematologic diseases and
cancers, today announced that it will release first quarter 2022
financial results Friday, May 6, 2022. Forma management will host
an investment community conference call at 8 a.m. Eastern Daylight
Time (EDT) on May 6, 2022 to discuss these financial results and
provide a business update.
Investors may participate by dialing (833) 301-1146 in the U.S.
or Canada, or (914) 987-7386 internationally, and by referring to
Conference ID 1879297. A live webcast of the conference call will
be available in the “News & Investors” section of Forma’s
website at www.formatherapeutics.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220429005013/en/
Investor: Mario Corso, +1 781-366-5726 Forma
Therapeutics, Inc. mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Forma Therapeutics Holdings Inc (NASDAQ): 0 recent articles
More Forma Therapeutics Holdings Inc News Articles